Member access

4-Traders Homepage  >  News

News

Latest NewsCompaniesMarketsEconomy & ForexCommoditiesHot NewsMost Read NewsRecomm.Business LeadersVideosCalendar 

Zogenix Inc. : Zogenix Announces Conference Call and Webcast to Present First Quarter 2013 Financial Results

05/03/2013 | 08:40am US/Eastern
Recommend:
0
Conference Call Scheduled for May 9, 2013 at 4:30 pm ET

SAN DIEGO, May 3, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, today announced it will release financial results for the first quarter ended March 31, 2013, after the market closes on Thursday, May 9, 2013, and will hold a conference call on this day at 4:30 p.m. ET (1:30 p.m. PT), to discuss these financial results and provide a company update.

To access the live webcast please visit the Company's Investor Relations website at ir.zogenix.com, and to participate, please dial (866) 318-8616 (U.S.) or (617) 399-5135 (International); participant passcode: 65838569.

The conference call will be hosted by Chief Executive Officer Roger L. Hawley, President Stephen J. Farr, Ph.D., and Executive Vice President and Chief Financial Officer Ann Rhoads.

A replay of the conference call will be available beginning May 9, 2013 at 6:30 p.m. ET (3:30 p.m. PT) until May 16, 2013, by dialing (888) 286-8010 (U.S.) or (617) 801-6888 (International); passcode: 23471504. A replay of the webcast will also be accessible on the Investor Relations website for one month, through June 9, 2013.

About Zogenix

Zogenix, Inc. (Nasdaq:ZGNX), with offices in San Diego and Emeryville, California, is a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain. Zogenix's first commercial product, SUMAVEL® DosePro® (sumatriptan injection) Needle-free Delivery System, was launched in January 2010 for the acute treatment of migraine and cluster headache. Zogenix's lead investigational product candidate, Zohydro™ ER (hydrocodone bitartrate), is an oral, extended-release formulation of various strengths of hydrocodone, without acetaminophen, intended for administration every 12 hours for around the clock management of moderate to severe chronic pain. In May 2012, Zogenix submitted to the FDA a New Drug Application for Zohydro ER. Zogenix's second investigational product candidate, Relday™, is a proprietary, long-acting injectable formulation of risperidone for the treatment of schizophrenia; an investigational new drug application was submitted to the FDA in May 2012. For additional information, please visit www.zogenix.com.

CONTACT: INVESTORS:
         Zack Kubow | The Ruth Group
         646.536.7020 | zkubow@theruthgroup.com

         MEDIA:
         Caitlin Cox | The Ruth Group
         646.536.7033 | ccox@theruthgroup.com
Zogenix
distributed by
Recommend :
0
React to this article
Latest news
Date Title
<1m ago KOENIG & BAUER : 13.5m sheets in first quarter
<1m ago TNB TENAGA NASIONAL BERHAD : Decline In Profit Before Tax Due To Lower Forex Translation Gain & High Generation Costs
<1m ago ROSTELEKOM : Rostelecom signs state contract with the Federal Education and Science Supervision Agency for video surveillance of the Unified State Exam
<1m ago HEMARAJ LAND AND DEVELOPMENT PUBLIC : Offers 10-Year Debentures With Interest Rate Up To 5.75%
<1m ago JIN CAI : Announcements and Notices - Sfc Announcement - High Concentration of Shareholding
<1m ago UKRSOTSBANK PAT : A general meeting of UniCredit Bank Shareholders took place on April 24, 2014
<1m ago AMERICAN BIO MEDICA : ABMC Reports Fourth Quarter and Year End 2013 Results
<1m ago POU SHENG : Form of proxy
<1m ago NASDAQ OMX : Reports Record First Quarter 2014 Results Apr 24, 2014
<1m ago WEST BANCORPORATION : Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)
Latest news
Advertisement
Hot News 
TRANS SIBERIAN GOLD : Asacha mining and production update
TRISTEL : 24/04/14 UHCW RNS Reach
THEOLIA VR : 2013 annual results
MOLINS : Proposed admission to trading on AIM
CREE : Patent Application Titled "Light Emitting Devices for Light Emitting Diodes (Leds)" Published Online
Most Read News
3h ago Juicy Apple buoys shares, euro volatility sinks
5h ago BLUNT BAYERN GIVEN A REAL MASTERCLASS ; CHAMPIONS LEAGUE Semi-final first leg
1d ago BUFFETT : moving oil by rail safely major industry concern
1d ago ACTIVISION BLIZZARD : Newest Skylanders® Game - Skylanders Trap TeamTM - Takes Toys-to-Life Phenomenon to New Levels by Bringing Digital Characters into the Physical World
1d ago WAL MART STORES : -Mart says former CEO Scott to retire from board
Most recommended articles
3h ago Juicy Apple buoys shares, euro volatility sinks
2h ago FTSE hits six-week high, miners lead
2d ago Barclays joins retreat from commodities as new rules bite
7d ago BLACKSTONE : earnings rise 30 percent, boosted by private equity gains
7m agoDJMOL MAGYAR OLAJ ES GAZIPARI NYRT : CEO-Chairman : Europe Has to Rely on Russian Oil, Gas for Now
Dynamic quotes  
ON
| OFF